Introduction: why "The Hormone Cure" is not really a book about hormones
Sara Gottfried is a graduate of Harvard Medical School, a board-certified gynaecologist, and a faculty member at Thomas Jefferson University. Her book "The Hormone Cure: Reclaim Balance, Sleep and Sex Drive; Lose Weight; Feel Focused, Vital, and Energized Naturally with the Gottfried Protocol" (Scribner, 2013) was one of the first to systematically combine mainstream endocrinology, laboratory diagnostics and lifestyle interventions for women's health.
Despite its marketing title, the book is not really "about hormones as chemistry". It is a systems view of regulation: how stress, sleep, nutrition, lifestyle and social ties determine what the laboratory will show in blood, and how laboratory data should be read within that system rather than in isolation.
I review the book from an endocrinologist's perspective: which of its ideas are supported by clinical data, which require caution, and which of its protocols are genuinely applicable in practice. The structure of the review is three key theses, their clinical implications, and a practical minimum.
🌀
#first_cortisol_is_the_first_domino
The central thesis of the book is that hormonal imbalances in women in the overwhelming majority of cases begin with cortisol dysregulation. Not with estrogen, not with the thyroid. Cortisol comes first because the HPA axis (hypothalamic-pituitary-adrenal axis) integrates signals of stress, circadian rhythm, sleep and metabolism, and its disruption triggers a cascade down the entire hormonal framework.
Mechanistically this operates through several channels. Chronically elevated cortisol: - suppresses TSH and reduces peripheral conversion of T4 to active T3 (Helmreich DL et al., *Stress* 2005, PMID 16513594) — hence the "low-T3 syndrome" in patients with chronic stress - competes with progesterone for the shared steroid precursor pregnenolone (the so-called "pregnenolone steal" concept) — therefore women under chronic stress frequently present with low-progesterone symptomatology: insomnia, anxiety, severe premenstrual syndrome - increases insulin resistance, visceral adiposity and disrupts deep-sleep architecture - induces peripheral aromatisation of testosterone to estradiol, contributing to estrogen dominance
The "pregnenolone steal" model as a mechanistic explanation is contested in contemporary endocrinology — actual steroidogenic pathways are more complex and there is no linear "theft" of pregnenolone. However, the clinically observed pattern — reduced testosterone and progesterone in chronic hypercortisolism — is reproducibly confirmed (Whirledge S et al., *Minerva Endocrinol* 2010, PMID 20595937). Gottfried's practical conclusion therefore stands, even if her mechanistic narrative is simplified.
Clinical implication: at the first visit of a patient presenting with symptoms of "hormonal imbalance" — irregular cycle, premenstrual syndrome, insomnia, central weight gain, low libido, fatigue — I never start with hormone replacement therapy. The first step is assessment of the cortisol rhythm. Minimum: a four-point salivary cortisol diurnal profile or a DUTCH test for an extended metabolomic readout. If the rhythm is inverted (low in the morning, high in the evening) or flat, treating sex hormones without correcting the HPA axis is futile.
A typical clinical scenario: a 38-year-old patient complaining of insomnia, fatigue and a 6 kg weight gain over two years. Laboratory: estradiol 220 pmol/L (normal), progesterone 28 nmol/L on day 21 (normal), TSH 2.4 (normal). Standard medicine: "your hormones are fine, try an antidepressant." Extended assessment in the Gottfried frame: diurnal cortisol with a peak at 23:00 (inverted rhythm), DHEA-S at the lower end of the reference range (adrenal exhaustion), free T3 at the lower end with a "normal" TSH, anti-TPO 145 (subclinical Hashimoto's). Diagnosis: HPA-axis dysregulation on a background of autoimmune thyroiditis. Management: sleep hygiene, selenium, vitamin D, circadian alignment, reassessment at three months — rather than levothyroxine or an antidepressant as first-line therapy.
🌀
#second_thyroid_not_by_TSH_alone
The second key idea is that standard thyroid testing by TSH alone misses a substantial proportion of clinically relevant dysfunction. Gottfried argues this both endocrinologically and clinically.
Endocrinologically the issue is that TSH is a pituitary signal, not a measure of tissue thyroid status. A patient can have a "normal" TSH (1.5–2.5 mIU/L) while at the same time showing impaired peripheral conversion of T4 to T3, elevated reverse T3 (rT3), positive thyroid antibodies (anti-TPO, anti-Tg) and clinical features of hypothyroidism. Mainstream medicine in this situation states that "thyroid function is normal" and refers the patient to a psychotherapist. Gottfried proposes an alternative: an extended panel.
The minimum extended panel per Gottfried: - TSH — interpreted with an optimal range of 0.5–2.0 mIU/L (not up to 4.5, as in most laboratories) - Free T4 - Free T3 — should sit in the upper third of the reference range for optimal wellbeing - Reverse T3 (rT3) — rises in stress, fasting and inflammation - The fT3/rT3 ratio as an index of active thyroid function - Antibodies to thyroid peroxidase (anti-TPO) and thyroglobulin (anti-Tg) - If iodine deficiency is suspected — urinary iodine excretion
This is not "a Gottfried innovation" — extended thyroid testing is described in the endocrine literature. Her contribution is that she translates this practice into the routine of a first visit rather than confining it to tertiary referral centres. A systematic review of thyroid function and quality of life in patients with "normal" TSH (Kelderman-Bolk N et al., *Eur J Endocrinol* 2015, PMID 25972054) demonstrated that a substantial proportion of symptomatic patients have conversion abnormalities despite a formally normal TSH.
Clinical implication: in my practice every patient with symptoms of fatigue, weight gain, brain fog or menstrual irregularity receives an extended thyroid panel as first-line investigation. It is not uncommon to find that a woman with a "normal" TSH of 3.2 has free T3 at the lower limit, anti-TPO 250 (confirmed autoimmune thyroiditis) and an elevated rT3. That is no longer "normal biochemistry" — it is a specific diagnosis with a specific management plan.
A separate practical point is T4-to-T3 conversion. This enzyme-dependent process (deiodinases D1 and D2) requires selenium, zinc, iron and vitamin D. Deficiency of any of these cofactors produces a picture of "normal T4, low T3, symptoms of hypothyroidism". In such patients my first-line approach is not levothyroxine but cofactor repletion: selenium 200 μg/day (as selenomethionine), zinc 15–25 mg/day, ferritin above 50 μg/L via iron supplementation if required, and 25(OH)D above 30 ng/mL. Reassessment at 8–12 weeks frequently shows normalisation of fT3 without hormonal therapy.
🌀
#third_estrogen_dominance_is_a_ratio
The third central idea: "estrogen dominance" is a phenomenon of ratio, not of absolute levels. The clinical picture — mastalgia, fibroids, endometriosis, severe premenstrual syndrome, lower-body weight gain, oedema, emotional lability in the luteal phase — develops when the relative level of estrogens exceeds the relative level of progesterone, even when absolute estradiol and progesterone sit within reference values.
The physiological cause in most cases is luteal-phase insufficiency. After the age of 35 the frequency of anovulatory cycles rises and progesterone falls faster than estrogen — hence the classic perimenopausal picture that begins a decade before menopause proper. Chronic stress accelerates this process through the same cascades (see cortisol above).
Additional factors Gottfried systematises: - Hepatic estrogen metabolism. The ratio of 2-hydroxyestrone (the protective pathway) to 16α-hydroxyestrone (potentially atherogenic) determines the "quality" of estrogen metabolism. Supporting phase II detoxification (glutathione, NAC, sulforaphane from broccoli, calcium-D-glucarate) shifts the balance toward the protective pathway - The gut microbiome (the estrobolome) — deconjugation of estrogens by bacterial β-glucuronidase leads to reabsorption and accumulation of estrogens - Adipose tissue as a site of aromatisation of testosterone to estradiol — therefore visceral obesity aggravates estrogen dominance, particularly in men and in postmenopausal women
Clinical implication: when assessing a woman's hormonal profile I do not look at individual data points but at ratios: estradiol to progesterone on day 21 of the cycle, estrogen metabolites (if DUTCH is performed) and metabolic markers (insulin, ferritin, total bilirubin as an indirect marker of phase II conjugation). And always — the clinical picture. Laboratory data without symptoms and symptoms without laboratory data are each incomplete.
🌀
#critique
What is strong in the book: the reframing of cortisol as the primary marker of hormonal health; the extended thyroid panel as a standard of first-line assessment; the conception of estrogen dominance through ratios rather than absolute levels; and the systematisation of lifestyle interventions (adaptogens, circadian rhythm, gut microbiome).
What warrants caution: the concept of "adrenal fatigue" as a clinical entity is not recognised in contemporary endocrinology — the correct framing is HPA-axis dysregulation, not "exhausted adrenals". Some of the BHRT (bioidentical hormone replacement therapy) protocols are described with enthusiasm exceeding the current evidence base, particularly subcutaneous testosterone pellets and unmonitored progesterone dosing. Botanical adaptogens (rhodiola, ashwagandha, maca) carry mid-level evidence — they are neither placebo nor magic.
What is critically important: the book is written for women with symptoms and a formally "normal" biochemistry who have been denied a diagnosis by mainstream medicine. It is not a manual for self-administered hormone therapy. An extended thyroid panel must be interpreted by an endocrinologist, BHRT must be prescribed by a physician, and nutraceuticals must be individualised with attention to drug interactions. Self-application of the book's protocols is a frequent reason patients present to me with a worsened imbalance.
What Gottfried omits or underweights: insulin resistance as a driver of estrogen dominance and polycystic ovary syndrome is treated superficially — for a substantial subset of patients metabolic health is primary and hormonal disturbance follows. The topic of PCOS as a multi-hormonal pathology (hyperandrogenism plus insulin resistance plus anovulation) is not given a structured treatment. Male hormonal physiology is barely mentioned, yet hormonal imbalances in men (low testosterone, aromatisation to estradiol in obesity, SHBG deficiency) are comparable in clinical significance. The book also does not address rare but clinically important endocrine disorders (macroprolactinoma, Cushing's syndrome, congenital adrenal hyperplasia), which require fundamentally different diagnostics.
🌀
#summary
Applied to a minimum viable clinical workflow, Gottfried's ideas reduce to the following.
Laboratory (when symptomatic for hormonal imbalance): TSH, free T4, free T3, reverse T3, anti-TPO, anti-Tg, salivary diurnal cortisol (four points) or DUTCH, estradiol and progesterone on day 21 (or baseline estradiol in the follicular phase), total testosterone and SHBG, DHEA-S, 25(OH)D, ferritin, and high-sensitivity CRP.
Circadian rhythm: a fixed sleep window of 22:30–07:00, ten minutes of morning light within the first 60 minutes after waking (anchors the morning cortisol peak), the last meal at least three hours before bed, and no screens for 60 minutes before sleep.
Nutrition: restriction of alcohol (it raises estrogens and suppresses phase II detoxification), regular intake of cruciferous vegetables (broccoli, cauliflower — sources of sulforaphane and DIM), adequate protein (1.2–1.6 g/kg body weight to support SHBG and steroidogenesis), and magnesium 300–400 mg/day in an active form (glycinate, citrate).
Stress management: a daily practice that regulates the HPA axis — ten minutes of diaphragmatic breathing, yoga nidra, meditation or a walk without podcasts. This is not an "optional nice-to-have"; it is a physiological intervention on the axis.
This is the baseline infrastructure. Individualised diagnostics and pharmacotherapy are built on top of it — but only once the infrastructure is in place.
🌀
#about_the_reviewer
Dr. Vladimir Pereligyn — endocrinologist. Functional medicine with a focus on preventive strategies: metabolic health, thyroid function, hormonal balance, and individualised risk profiling based on extended laboratory diagnostics. Consultations in person and online: [universum.earth/consultation](/consultation). App Store: Teremok (type 2 diabetes, remission).
🌀
Source
▸ Gottfried S. *The Hormone Cure: Reclaim Balance, Sleep and Sex Drive; Lose Weight; Feel Focused, Vital, and Energized Naturally with the Gottfried Protocol*. Scribner, New York, 2013. ISBN 978-1451666953. 448 pages.
Additional reading on the topics of this review: ▸ Helmreich DL, Parfitt DB, Lu XY, Akil H, Watson SJ. Relation between the hypothalamic-pituitary-thyroid (HPT) axis and the hypothalamic-pituitary-adrenal (HPA) axis during repeated stress. *Stress* 2005;8(1):75-84. PMID 16513594 ▸ Kelderman-Bolk N, Visser TJ, Tijssen JP, Berghout A. Quality of life in patients with primary hypothyroidism related to BMI. *Eur J Endocrinol* 2015;173(4):507-15. PMID 25972054 ▸ Whirledge S, Cidlowski JA. Glucocorticoids, stress, and fertility. *Minerva Endocrinol* 2010;35(2):109-25. PMID 20595937 ▸ Adlercreutz H, Höckerstedt K, Bannwart C, et al. Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens. *J Steroid Biochem* 1987;27(4-6):1135-44. PMID 2826904 ▸ Plottel CS, Blaser MJ. Microbiome and malignancy. *Cell Host Microbe* 2011;10(4):324-35. PMID 22018232
🌀
*This review reflects the author's clinical interpretation and does not replace consultation with a physician. Before changing therapy, diagnostic protocols or lifestyle, discuss the plan with your treating specialist.*
